Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients

• Published in: Pediatric critical care medicine Vol. 18; no. 9; pp. e388 - e394
• Main Authors: Avedissian, Sean N, Bradley, Erin, Zhang, Diana, Bradley, John S, Nazer, Lama H, Tran, Tri M, Nguyen, Austin, Le, Jennifer
• Format: Journal Article
• Language: English
• Published: United States 01-09-2017
• Subjects: Adolescent; Anti-Bacterial Agents - pharmacokinetics; Biomarkers - metabolism; Child; Child, Preschool; Creatinine - metabolism; Critical Care; Critical Illness; Drug Monitoring; Female; Glomerular Filtration Rate; Humans; Infant; Linear Models; Male; Metabolic Clearance Rate; Models, Theoretical; Retrospective Studies; Vancomycin - pharmacokinetics; Young Adult
• ISSN: 1529-7535
• DOI: 10.1097/pcc.0000000000001228

The objectives of this study were to: 1) evaluate the prevalence of augmented renal clearance in critically ill pediatric patients using vancomycin clearance; 2) derive the pharmacokinetic model that best describes vancomycin clearance in critically ill pediatric patients; and 3) correlate vancomycin clearance with creatinine clearance estimated by modified Schwartz or Cockcroft-Gault.
Retrospective, two-center, cohort study from 2003 to 2016.
Clinical drug monitoring services in the PICUs at two tertiary care, teaching hospitals.
Children from 1 to 21 years old.
None.
Identify patients with augmented renal clearance (vancomycin clearance ≥ 130 mL/min/1.73 m used as definition of augmented renal clearance). Derive final population-based pharmacokinetic model and estimate individual patient pharmacokinetic parameters. Compare estimated glomerular filtration rate (modified Schwartz or Cockcroft-Gault depending on age < or ≥ 17 yr) with vancomycin clearance. Augmented renal clearance was identified in 12% of 250 total subjects. The final population-based pharmacokinetic model for vancomycin clearance (L/hr) was 0.118 × weight (e). Median vancomycin clearance in those with versus without augmented renal clearance were 141.3 and 91.7 mL/min/1.73 m, respectively (p < 0.001). By classification and regression tree analysis, patients who were more than 7.9 years old were significantly more likely to experience augmented renal clearance (17% vs 4.6% in those ≤ 7.9 yr old; p = 0.002). In patients with augmented renal clearance, 79% of 29 had vancomycin trough concentrations less than 10 µg/mL, compared with 52% of 221 in those without augmented renal clearance (p < 0.001). Vancomycin clearance was weakly correlated to the glomerular filtration rate estimated by the modified Schwartz or Cockcroft-Gault method (Spearman R = 0.083).
Augmented renal clearance was identified in one of 10 critically ill pediatric patients using vancomycin clearance, with an increase of approximately 50 mL/min/1.73 m in those with augmented renal clearance. As augmented renal clearance results in subtherapeutic antibiotic concentrations, optimal dosing is essential in those exhibiting augmented renal clearance.